Using a new oral medication to prevent Type 1 Diabetes by targeting immune cells in the gut
Restoring Tolerance with an Oral AMPK Agonist Nanomedicine Targeting Intestinal Dendritic Cells as a Preventative Therapy for Type 1 Diabetes
['FUNDING_OTHER'] · QRONO, INC · NIH-11007750
This study is testing a new oral medication called QR402 that aims to help people at risk of Type 1 Diabetes by using tiny particles to support the immune system and protect insulin-producing cells from being damaged.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | QRONO, INC (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-11007750 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a novel oral medication, QR402, that targets specific immune cells in the intestines to prevent the destruction of insulin-producing cells in Type 1 Diabetes (T1D). The approach involves using nanoparticles to deliver an AMPK pathway agonist that promotes the development of tolerogenic dendritic cells, which are crucial for maintaining immune balance and preventing autoimmune responses. By enhancing the function of these immune cells, the research aims to restore tolerance and potentially halt the progression of T1D before it fully develops. This could provide a new preventative strategy for individuals at risk of T1D.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at high risk of developing Type 1 Diabetes, particularly those with early immunological signs of the disease.
Not a fit: Patients who are already diagnosed with Type 1 Diabetes and require insulin therapy may not benefit from this preventative approach.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking preventative therapy for Type 1 Diabetes, reducing the incidence of the disease and improving the quality of life for at-risk individuals.
How similar studies have performed: While this approach is novel in targeting dendritic cells for T1D prevention, similar strategies in other autoimmune diseases have shown promise, indicating potential for success.
Where this research is happening
PITTSBURGH, UNITED STATES
- QRONO, INC — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CARGILL, CHRISTINA PAIGE — QRONO, INC
- Study coordinator: CARGILL, CHRISTINA PAIGE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.